BIRC8 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL12851841	1.00	6/20
SCHEMBL9973388	0.76	6/20
SCHEMBL12851690	1.00	5/20
SCHEMBL12851751	1.00	5/20
SCHEMBL9973415	0.97	5/20
SCHEMBL12571264	0.97	5/20
SCHEMBL12851886	0.92	5/20
SCHEMBL12852024	0.92	5/20
SCHEMBL9973393	0.77	5/20
SCHEMBL1331007	0.55	5/20
SCHEMBL1331008	0.55	5/20
SCHEMBL1329088	0.52	5/20
SCHEMBL12105346	1.00	4/20
SCHEMBL12108408	1.00	4/20
SCHEMBL12851914	1.00	4/20
SCHEMBL12855119	0.96	4/20
SCHEMBL9975121	0.81	4/20
SCHEMBL12851926	0.81	4/20
SCHEMBL12851818	0.75	4/20
SCHEMBL9973499	0.70	4/20

Clinical trials — most relevant to BIRC8 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma	PHASE4	UNKNOWN
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer	PHASE4	UNKNOWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)	PHASE1/PHASE2	WITHDRAWN
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis	PHASE2	COMPLETED
Disulfiram in Rheumatoid Arthritis	PHASE2	NOT_YET_RECRUITING
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC	PHASE2	COMPLETED
Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma	PHASE1	COMPLETED
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas	PHASE1	COMPLETED
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma	PHASE1	COMPLETED
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma	PHASE1	ACTIVE_NOT_RECRUITING
FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma	PHASE1	WITHDRAWN
Studying TAK-243 in Patients With Advanced Cancer	PHASE1	RECRUITING
Potential Role of microRNA 410 and BIRC7 Pathways in Recurrent Spontaneous Miscarriage	nan	COMPLETED
Inflammasomes in Cell Death in FTMH, ERM, and RRD	nan	COMPLETED
Dietary Intervention With High Phenolic EVOO in CLL	nan	COMPLETED
Effect of Periodontal Treatment on Inflammasome Proteins in Periodontal Diseases	nan	UNKNOWN
Circulating Markers for Ischemic Heart Disease	nan	RECRUITING
Apoptosis Markers in Aggressive Periodontitis	nan	COMPLETED
Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer	nan	RECRUITING
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure	nan	RECRUITING
Analysis of the Variation in Caspase-8 Availability and Cleavage in Oral Squamous Cell Carcinoma	nan	UNKNOWN
New Signaling Pathway Targeting Systemic Lupus Erythematosus	nan	UNKNOWN
Role NLRP3 Inflammasome in Weight Loss Following Sleeve Gastrectomy in Morbidly Obese Patients	nan	UNKNOWN
Molecular Mechanism of Nasopharyngeal Carcinoma	nan	UNKNOWN
Probiotics and Systemic Inflammation in Patients With Metabolic Syndrome and High Cardiovascular Risk	nan	WITHDRAWN
Autophagy Bladder Cancer	nan	UNKNOWN
Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia	nan	RECRUITING
Nucleotide Protein -3 in Epileptic Children	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a BIRC8 binder may also engage these)

Protein	Name	Similarity
Q95M71	—	1.000	Q95M71 →
Q95M72	—	1.000	Q95M72 →
Q9R0I6	—	0.994	Q9R0I6 →
Q5BKL8	—	0.993	Q5BKL8 →
A5D8Q0	—	0.993	A5D8Q0 →
XIAP	E3 ubiquitin-protein ligase XIAP	0.991	landscape →
O62640	—	0.990	O62640 →
Q62210	—	0.990	Q62210 →
BIRC3	Baculoviral IAP repeat-containing protein 3	0.989	landscape →
Q90660	—	0.989	Q90660 →
O08863	—	0.988	O08863 →
BIRC2	Baculoviral IAP repeat-containing protein 2	0.987	landscape →
A1E2V0	—	0.986	A1E2V0 →
Q60989	—	0.986	Q60989 →
Q24307	—	0.986	Q24307 →
F4IDQ6	—	0.984	F4IDQ6 →
Q04638	—	0.984	Q04638 →
KAT8	Histone acetyltransferase KAT8	0.984	landscape →
Q5XI06	—	0.983	Q5XI06 →
Q19546	—	0.983	Q19546 →
Q9D3R6	—	0.983	Q9D3R6 →
Q5XI69	—	0.982	Q5XI69 →
KDM5B	Lysine-specific demethylase 5B	0.982	landscape →
O01738	—	0.982	O01738 →
Q9H1H9	—	0.982	Q9H1H9 →
O76924	—	0.982	O76924 →
O94393	—	0.981	O94393 →
B4NBB0	—	0.981	B4NBB0 →
Q13156	—	0.981	Q13156 →
Q6PE54	—	0.981	Q6PE54 →